ODAC to weigh in on approving olaparib sooner than later
By Mari Serebrov
Monday, June 23, 2014
Is a seven-month improvement in progression-free survival (PFS) in a subgroup of a single clinical trial enough to grant accelerated approval to Astrazeneca plc's olaparib as the first maintenance therapy for BRCA-mutated ovarian cancers?
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.